Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mutlu Hızal
Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?
Future Oncology
Medicine
Cancer Research
Oncology
Related publications
Brain Metastases From Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors
Clinical Genitourinary Cancer
Oncology
Urology
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Economic Evaluation of First Line Treatment for Advanced Non Small Cell Lung Cancer Using Tyrosine Kinase Inhibitors in Malaysia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Concomitant Oral Tyrosine Kinase Inhibitors and Bisphosphonates in Advanced Renal Cell Carcinoma With Bone Metastases
British Journal of Cancer
Cancer Research
Oncology
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Pcn190 - Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Population-Based Study Examining the Effect of Tyrosine Kinase Inhibitors on Survival in Metastatic Renal Cell Carcinoma in Alberta and the Role of Nephrectomy Prior to Treatment
Canadian Urological Association Journal
Urology
Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
